Open Journal Systems

Clinical Study on Xiaoaiping Oral Liquid Combined with Bevacizumab in Treatment of Advanced Non-small Cell Lung Cancer

Y. Wang (Chongqing Medical University, Chongqing, China)

Abstract


Objective. To study the clinical efficacy of Xiaoaiping Oral Liquid combined with Bevacizumab Injection in treatment of advanced non-small cell lung cancer. Methods. Patients (128 cases) with advanced non-small cell lung cancer in the First Affiliated Hospital of Henan University from January 2016 to January 2019 were randomly divided into control and treatment groups, and each group had 64 cases. Patients were treated with TC regimen (carboplatin + paclitaxel). Patients in the control group were iv administered with Bevacizumab Injection at the first day, 7.5 mg/kg. Patients in the treatment group were po administered with Xiaoaiping Oral Liquid on the basis of the control group, 10 mL/time, three times daily. A course had 21 days, and patients in two groups were treated for 4 courses. After treatment, the clinical efficacies were evaluated, and serum levels of CEA, NSE, and CA125, KPS score, progression-free survival time (PFS), total survival time (OS), and adverse reactions were compared between two groups. Results. After treatment, DCR (78.12% vs 67.19%) and ORR (64.06% vs 51.56%) in the treatment group were significantly higher than those in the control group (P < 0.05). After treatment, the serum levels of CEA, NSE and CA125 in the two groups were significantly reduced (P < 0.05). And the tumor markers in the treatment group were significantly lower than those in the control group (P < 0.05). After treatment, KPS scores in two groups were significantly decreased (P < 0.05), and the KPS score in the treatment group was significantly lower than that in the control group (P < 0.05). After treatment, PFS and OS in the treatment group were significantly higher than those in the control group (P < 0.05). The incidence of gastrointestinal reaction, thrombocytopenia, leukopenia and liver dysfunction in the treatment group was significantly lower than that in the control group (P < 0.05). Conclusion. Xiaoaiping Oral Liquid combined with Bevacizumab Injection has clinical curative effect in treatment of advanced non-small cell lung cancer, can improve the quality of life of patients and reduce the serum levels of tumor markers, which is worthy of clinical application.


Keywords


Xiaoaiping Oral Liquid; Bevacizumab Injection; Carboplatin Injection; Paclitaxel Injection; Advanced non-small cell lung cancer; Survival time; Tumor marker

Full Text:

PDF

References


Wang Yujin, Huang Jingyu, Hu Weidong, et al. Clinical epidemiological analysis of 2403 cases of lung cancer [J]. Journal of International Oncology, 2019, 46(8): 460-465.

Wang Dazhi. Cost-effectiveness analysis and epidemiological clinical evaluation of four chemotherapy regimens for non-small cell lung cancer [J]. Anhui Medicine, 2007, 11(2): 174-176.

Jinlong. The etiology and treatment of non-small cell lung cancer [J]. Journal of the Chinese Academy of Sciences, 2009, 8(6): 76-79.

Chen Xiaoling, Fang Jian. Research status of bevacizumab in non-small cell lung cancer [J]. Chinese Journal of Clinical Oncology, 2011, 38(12): 747-750.

Bi Minghong. The progress of bevacizumab in the treatment of non-small cell lung cancer [J]. Clinical Pulmonary Journal, 2018, 23(10): 1909-1914.

Li Jing, Zhang Hua. Clinical observation of Zefei combined with Xiaoaiping in the treatment of 38 cases of advanced non-small cell lung cancer [J]. China Traditional Chinese Medicine Science and Technology, 2009, 16(3):206.

Zhou Jichang. Practical Medical Oncology [M]. Beijing: People's Medical Publishing House, 1999: 22.

Yang Xuening, Wu Yilong. Evaluation criteria for therapeutic efficacy of solid tumors-RECIST[J]. Evidence-based Medicine, 2004, 4(2): 85-90, 111.

Wan Chonghua. Measurement and evaluation method of life quality [M]. Kunming: Yunnan University Press, 1999: 224.

Sun Yan, Shi Yuankai. Handbook of Clinical Oncology [M]. 5th edition. Beijing: People's Medical Publishing House. 2007: 160-164.

Hu Guangsheng, Wang Yunqi. Research progress in the treatment of non-small cell lung cancer with traditional Chinese medicine [J]. Herald of Chinese Medicine, 2015, 21(2): 59-61.

Jinlong. New progress in the etiology and treatment of non-small cell lung cancer [J]. Journal of Dali University: Comprehensive Edition, 2009, 8(6): 76-79.

Zhang Yuxiang, Hao Dengrong. Analysis of the effectiveness of pemetrexed combined with bevacizumab in the maintenance phase of non-squamous non-small cell lung cancer[J]. International Journal of Respiration, 2019, 39(8): 567-571 .

Zhang Yanian. The clinical study of Kangai injection combined with bevacizumab and DP regimen in the treatment of non-small cell lung cancer [J]. Modern Medicine and Clinics, 2019,34(12): 3690-3695.

Jiang Youguo, Wang Taoyuan, Liu Juntao, et al. Clinical study of bevacizumab combined with icotinib in the treatment of advanced non-small cell lung cancer[J]. Modern Medicine and Clinics, 2018, 33(12): 3259- 3263.

Wang Wenyu, Zhou Yun, Zhang Xiaoju, et al. Clinical observation of Xiaoaiping injection combined with chemotherapy in the treatment of advanced non-small cell lung cancer [J]. Journal of Clinical Oncology, 2009, 14(10): 936-938.

Zhang Ruixing, Yue Jiangtao, Wang Tianping, et al. Clinical observation of Xiaoaiping injection combined with chemotherapy in the treatment of advanced non-small cell lung cancer [J]. Basic and Clinical Oncology, 2012, 25(5): 438-440.

Xue Shan, Cha Qiongfang, Zhao Xuji, et al. CEA, CA125, CYFRA21-1, NSE and SCC for non-small cell lung cancer chemotherapy effect and evaluation value[J]. Shandong Medicine, 2015, 25(25) : 8-11.



DOI: http://dx.doi.org/10.30564/amor.v6i5.286

Refbacks

  • There are currently no refbacks.


Copyright (c) 2020 Y. Wang

Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.